Carlos Oyarzun given four-year ban for FG-4592 positive
Chilean rider given suspension after positiv▨e at 2015 Pan Ameཧrican Games
168澳洲5最新开奖结果:Carlos Oyarzun has been handed a four-year suspension by the UCI following a positive t﷽est for FG-4592 at the 2015 Pan American Games. Over a ♊year after Oyarzun was provisionally suspended, the UCI confirmed that he would serve a ban.
"The Union Cycliste Internationale (UCI) announces that the UCI Anti-Doping Tribunal has rendered its decision in the case involving Carlos Oyarzun," a statemen꧒t on the UCI's website read. "The Anti-Doping Tribunal found the rider guilty of an anti-doping rule violation (Use of a prohibited substance) and imposed a 4-year period of ineligibility on the rider."
Oyarzun, who won the time trial event, was 168澳洲5最新开奖结果:one of two riders to produce po♏sitive samples at the Pan American Games. Colombia's Maria Luisa Calle returned an adverse analytical finding fo🐓r the growth hormone stimulant GHRP2. She was also handed a four-year suspension in March of this year.
Oyarzun is only the second cyclist to be banned from racing for taking FG-4592. Italian rider Fabio Taborre 168澳洲5最新开奖结果:also tested positive for the drug in July of last year𒆙 and was handed a four-year sus✱pension this May.
FG-4592, which is also known as Roxa👍dustat, is a blood-boosting drug that looks to stimulate the body's natural production of EPO and can be taken in tablet form. 🐎Although not available on the open market at the time, WADA added it to their list of banned substances. French race walker Bertrand Moulinet was one of the first to test positive for the substance in March 2015.
Chilean rider Oyarzun is a two-time Pan American champion, once in the road race in 2010 and once in the time trial, in 2013. He has spent the past two seasons racing for the Croatian Continental team Keith Mobel-Partisan. The 34-year-old also spent a year on the 💝Movistar team in 2011 and during that time made his one and only Grand Tour appearance aﷺt the Giro d'Italia.
The late🃏st race content, interviews, features, reviews and expert bu⭕ying guides, direct to your inbox!